Indivior Pharmaceuticals financials
$36.59−0.79%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 |
|---|---|---|---|
| Revenue | $1.24B | $1.19B | $1.09B |
| Gross profit | $993.0M | $957.0M | $919.0M |
| Gross margin | 80.1% | 80.6% | 84.1% |
| Operating income | $262.0M | $38.0M | -$154.0M |
| Net income | $210.0M | $7.0M | -$126.0M |
| Net margin | 16.9% | 0.6% | −11.5% |
| Diluted EPS | $1.64 | $0.05 | $-0.92 |
| EBITDA | $275.0M | $250.0M | $262.0M |
| Operating cash flow | -$27.0M | $36.0M | -$300.0M |
| Free cash flow | -$93.0M | $7.0M | -$308.0M |
| Diluted shares | 128.0M | 133.0M | 137.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|
| Cash & equivalents | $195.0M | $319.0M | $316.0M |
| Short-term investments | $0.00 | $1.0M | $94.0M |
| Total debt | $319.0M | $333.0M | $240.0M |
| Total assets | $1.20B | $1.32B | $1.76B |
| Total liabilities | $1.30B | $1.65B | $1.95B |
| Shareholders' equity | -$99.0M | -$337.0M | -$190.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology